Jul 22, 2019

AbbVie blocked competition with patents and M&A to protect sales

Pharma CEOs, including AbbVie's Richard Gonzalez, testify on Capitol Hill. Photo: Win McNamee/Getty Images

Humira is the world’s most profitable drug, but it’s also a prime example of Big Pharma's business model, as Sy Mukherjee lays out well in a big Fortune story.

The big picture: "These companies became like great big record labels: reliant on talent spotters going out and finding new artists," SVB Leerink analyst Geoffrey Porges tells Fortune.

Details: AbbVie, which now sells Humira, did not invent the drug. It bought the smaller biotech that did.

  • Once it owned Humira, AbbVie protected it with a thicket of patents — roughly 136 of them, and it has aggressively sued to protect those patents. It has also raised its list prices every year and spent big on marketing.
  • And now, with Humira competition inevitably approaching, AbbVie is buying Allergan, where it will benefit from the lucrative market for Botox and other cosmetic products.

Why it matters: This is increasingly how the industry works.

  • Small biotechs patented two-thirds of the novel drugs the FDA approved last year; Big Pharma companies only developed one-quarter of them.
  • Most Big Pharma companies are expected to reduce their research and development budgets.

The bottom line, per Mukherjee: "Hundreds of millions go to marketing and legal-fortress building, while innovation and scientific discovery — ostensibly the beating heart of the biopharmaceutical industry — is often imported from the outside."

Go deeper:

Go deeper

How Democrats want to limit drug prices

Illustration: Rebecca Zisser/Axios

The Democratic presidential candidates' plans to lower drug prices are much more aggressive than what the party has supported in the past.

Between the lines: There are big differences among the candidates' platforms, but the entire debate has shifted to the left.

Go deeperArrowAug 8, 2019

Trump's next move on lowering drug prices

Phot: Chip Somodevilla/Getty Images

The White House is preparing another big executive order on drug prices, Reuters scooped last night.

The big picture: Citing industry sources who had discussed the plan with the administration, Reuters says that it would likely seek to lower prices in Medicare Part D, which covers drugs you pick up at the pharmacy counter. The administration's most sweeping proposal to date — to piggyback off of the lower prices in European countries — was limited to Part B, which covers drugs administered by a doctor.

Go deeperArrowJul 26, 2019

HHS announces pathways for prescription drug importation

HHS Secretary Alex Azar. Photo: Alex Wong/Getty Images

The Trump administration announced Wednesday that it is taking steps to open the door for prescription drugs to be imported into the U.S. from other countries.

The big picture: Drug importation has long been a policy idea championed mostly by Democrats, but there are plenty of reasons to be skeptical that it'll have much of an impact on drug prices — beginning with other countries' lack of enthusiasm for sending us their drugs.

Go deeper: Importing prescription drugs from Canada is tougher than it sounds

Keep ReadingArrowJul 31, 2019